Tenax Therapeutics (NASDAQ:TENX) Shares Cross Above 200-Day Moving Average – What’s Next?

by · The Cerbat Gem

Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report)’s share price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.66 and traded as high as $5.09. Tenax Therapeutics shares last traded at $4.93, with a volume of 57,291 shares.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on TENX shares. StockNews.com started coverage on shares of Tenax Therapeutics in a report on Thursday, September 26th. They set a “sell” rating on the stock. William Blair initiated coverage on Tenax Therapeutics in a research report on Monday, September 30th. They set an “outperform” rating for the company. Guggenheim began coverage on Tenax Therapeutics in a research note on Monday, October 14th. They issued a “buy” rating and a $16.00 price target for the company. Leerink Partnrs upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday, October 24th. Finally, Leerink Partners started coverage on shares of Tenax Therapeutics in a research note on Thursday, October 24th. They set an “outperform” rating and a $16.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Tenax Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Get Our Latest Research Report on TENX

Tenax Therapeutics Trading Down 3.1 %

The business has a 50-day moving average price of $3.95 and a 200 day moving average price of $3.68.

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.99) by $0.16. On average, sell-side analysts predict that Tenax Therapeutics, Inc. will post -6.62 earnings per share for the current fiscal year.

Tenax Therapeutics Company Profile

(Get Free Report)

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

Read More